Unknown

Dataset Information

0

Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: A retrospective cohort study.


ABSTRACT:

Background

Studies report hypercoagulability in coronavirus disease 2019 (COVID-19), leading many institutions to escalate anticoagulation intensity for thrombosis prophylaxis.

Objective

To determine the bleeding risk with various intensities of anticoagulation in critically ill patients with COVID-19 compared with other respiratory viral illnesses (ORVI).

Patients/methods

This retrospective cohort study compared the incidence of major bleeding in patients admitted to an intensive care unit (ICU) within a single health system with COVID-19 versus ORVI. In the COVID-19 cohort, we assessed the effect of anticoagulation intensity received on ICU admission on bleeding risk. We performed a secondary analysis with anticoagulation intensity as a time-varying covariate to reflect dose changes after ICU admission.

Results

Four hundred and forty-three and 387 patients were included in the COVID-19 and ORVI cohorts, respectively. The hazard ratio of major bleeding for the COVID-19 cohort relative to the ORVI cohort was 1.26 (95% confidence interval [CI]: 0.86-1.86). In COVID-19 patients, an inverse-probability treatment weighted model found therapeutic-intensity anticoagulation on ICU admission had an adjusted hazard ratio of bleeding of 1.55 (95% CI: 0.88-2.73) compared with standard prophylactic-intensity anticoagulation. However, when anticoagulation was assessed as a time-varying covariate and adjusted for other risk factors for bleeding, the adjusted hazard ratio for bleeding on therapeutic-intensity anticoagulation compared with standard thromboprophylaxis was 2.59 (95% CI: 1.20-5.57).

Conclusions

Critically ill patients with COVID-19 had a similar bleeding risk as ORVI patients. When accounting for changes in anticoagulation that occurred in COVID-19 patients, therapeutic-intensity anticoagulation was associated with a greater risk of major bleeding compared with standard thromboprophylaxis.

SUBMITTER: Halaby R 

PROVIDER: S-EPMC8250316 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

2022-02-28 | GSE197259 | GEO
| S-EPMC7863679 | biostudies-literature
| S-EPMC8362592 | biostudies-literature
| S-EPMC7444469 | biostudies-literature
| S-EPMC10816646 | biostudies-literature
2023-04-29 | GSE206264 | GEO
| S-EPMC7321912 | biostudies-literature
| S-EPMC7409727 | biostudies-literature
| S-EPMC7668013 | biostudies-literature
| S-EPMC8294630 | biostudies-literature